The Milan Cell and Gene Center of Excellence at AGC Biologics will produce LVV material for Treg cell therapy candidates.

AI is increasingly being adopted by sponsors for various applications in clinical trials, including optimising trial design, ...

Changes to Health Technology Assessment (HTA) in Europe offer new opportunities to streamline processes and get innovative ...

Greeks remain 'spectators' to pharmaceutical innovation. New medicines are frequently approved, but never reach patients.

A recent study reveals that the average duration of ADHD medication for children and adolescents is more than three years. However, reliable, controlled data on the safety of marketed ADHD medicines ...

Topline results were released from the phase 3 MAPLE-HCM trial, which compared aficamten with metoprolol in 175 adults with ...

Zynyz is the first and only FDA-approved first-line treatment for adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal.

OS Therapies Inc. ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported first quarter 2025 financial results ended ...

Families report devastating outcomes following Librela injections for dogs, citing paralysis and death. Meanwhile, Zoetis maintains side effects are rare.

Incyte INCY announced that the FDA has approved its new drug, Zynyz (retifanlimab-dlwr), a PD-1 inhibitor, for treating a new ...

SHELTON, CT / ACCESS Newswire / May 16, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending March 31, 2025 ...

Conference call and webcast rescheduled for 8:30 a.m. Eastern Time on Monday, May 19 NEW YORK, May 15, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.